Insider Selling: Lantheus Holdings, Inc. (NASDAQ:LNTH) CAO Sells $559,074.80 in Stock

Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Rating) CAO Andrea Sabens sold 7,705 shares of the company’s stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $72.56, for a total value of $559,074.80. Following the transaction, the chief accounting officer now owns 63,626 shares of the company’s stock, valued at approximately $4,616,702.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Andrea Sabens also recently made the following trade(s):

• On Tuesday, January 17th, Andrea Sabens sold 386 shares of Lantheus stock. The shares were sold at an average price of $52.97, for a total value of $20,446.42.
• On Thursday, December 15th, Andrea Sabens sold 386 shares of Lantheus stock. The shares were sold at an average price of $53.75, for a total value of $20,747.50.

Lantheus Trading Down 2.6 %

NASDAQ LNTH opened at $71.26 on Friday. Lantheus Holdings, Inc. has a 12 month low of $47.46 and a 12 month high of $87.47. The stock has a market cap of $4.81 billion, a P/E ratio of 209.59 and a beta of 0.64. The stock’s fifty day moving average price is $59.64 and its 200-day moving average price is $64.18. The company has a current ratio of 2.74, a quick ratio of 2.59 and a debt-to-equity ratio of 1.25.

Lantheus (NASDAQ:LNTH – Get Rating) last released its earnings results on Thursday, February 23rd. The medical equipment provider reported $1.28 EPS for the quarter, topping analysts’ consensus estimates of $0.87 by $0.41. Lantheus had a return on equity of 51.60% and a net margin of 3.00%. The firm had revenue of $263.17 million for the quarter, compared to analysts’ expectations of $244.61 million. As a group, equities analysts forecast that Lantheus Holdings, Inc. will post 4.46 EPS for the current fiscal year.

Institutional Investors Weigh In On Lantheus

A number of institutional investors have recently modified their holdings of LNTH. CWM LLC boosted its position in shares of Lantheus by 82.1% during the third quarter. CWM LLC now owns 366 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 165 shares during the last quarter. Wipfli Financial Advisors LLC purchased a new stake in shares of Lantheus during the third quarter valued at $30,000. Wolverine Asset Management LLC purchased a new stake in shares of Lantheus during the fourth quarter valued at $36,000. Coppell Advisory Solutions Corp. purchased a new stake in shares of Lantheus during the fourth quarter valued at $48,000. Finally, Globeflex Capital L P boosted its position in shares of Lantheus by 10,600.0% during the fourth quarter. Globeflex Capital L P now owns 1,070 shares of the medical equipment provider’s stock valued at $55,000 after buying an additional 1,060 shares during the last quarter. 97.62% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages recently commented on LNTH. JMP Securities began coverage on Lantheus in a report on Wednesday. They set an “outperform” rating and a $120.00 target price for the company. StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a report on Monday, February 27th. SVB Leerink assumed coverage on Lantheus in a report on Wednesday, November 30th. They issued an “outperform” rating for the company. Finally, Mizuho increased their price objective on Lantheus from $105.00 to $115.00 and gave the stock a “buy” rating in a report on Friday, February 24th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $107.33.

Lantheus Company Profile

(Get Rating)

Lantheus Holdings, Inc engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments.